<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>79</patient-age><report-id>PHHY2012FR122194</report-id><gender>female</gender><reactions><reaction>Bullous eruption/ bullous lesions/diffuse bullous lesions with serous liquid inside</reaction><reaction>Blisters/appearance of oral bullae/one bulla on posterior and lateral pharyngeal wall</reaction><reaction>Urticaria on thorax and abdomen</reaction><reaction>Upper limbs erythema with progressive spread to the whole body/diffuse papullar erythema</reaction><reaction>Multiple itching lesions</reaction><reaction>Hypereosinophilia / eosinophilia</reaction><reaction>Oligoanuric renal failure/acute functional renal failure</reaction><reaction>Lower limbs oedema up to knees</reaction><reaction>Persistant arterial hypotension</reaction><reaction>Altered thyroid function</reaction><reaction>Positive with E.coli</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>NISISCO</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>ATENOLOL </drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>TAHOR</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>GLUCOPHAGE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>DIAMICRON</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>DOLIPRANE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>PROFENID</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>TRAMADOL</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>KETUM</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>AERIUS</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>PRAVASTATIN</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>AMOXICILLIN</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Hypertension</indication><indication>Dyslipidaemia</indication><indication>Type 2 diabetes mellitus</indication><indication>Blister</indication></indications><patient-age>79</patient-age><outcomes><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>France</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4149676_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152623</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>3</safetyreportversion>
		<safetyreportid>PHHY2012FR122194</safetyreportid>
		<primarysourcecountry>FR</primarysourcecountry>
		<occurcountry>FR</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-12-31</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-18</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012FR122194</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<linkedreport>
			<linkreportnumb>late due to CPO DS&amp;E</linkreportnumb>
		</linkedreport>
		<linkedreport>
			<linkreportnumb>2013-SPON-039</linkreportnumb>
		</linkedreport>
		<linkedreport>
			<linkreportnumb>2013-0009</linkreportnumb>
		</linkedreport>
		<linkedreport>
			<linkreportnumb>2012-SPON-532</linkreportnumb>
		</linkedreport>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>FR</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>FR</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientonsetage>79</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Type 2 diabetes mellitus</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Dyslipidaemia</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Renal failure chronic</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Nephropathy</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Resuscitation</patientepisodename>
				<patientmedicalcomment>bullae boring</patientmedicalcomment>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Bullous eruption/ bullous lesions/diffuse bullous lesions with serous liquid inside</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Bullous eruption</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Dermatitis bullous</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201208</reactionstartdate>
				<reactionoutcome code="2">recovering/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Blisters/appearance of oral bullae/one bulla on posterior and lateral pharyngeal wall</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Blisters</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Blister</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Urticaria on thorax and abdomen</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Urticaria</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Urticaria</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Upper limbs erythema with progressive spread to the whole body/diffuse papullar erythema</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Erythema diffuse</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Erythema</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Multiple itching lesions</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Itching</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Pruritus</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Hypereosinophilia / eosinophilia</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Hypereosinophilia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Eosinophilia</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201208</reactionstartdate>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Oligoanuric renal failure/acute functional renal failure</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Anuric renal failure</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Renal failure</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Lower limbs oedema up to knees</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Edema lower limb</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Oedema peripheral</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Persistant arterial hypotension</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Arterial hypotension</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hypotension</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121123</reactionstartdate>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Altered thyroid function</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Thyroid function abnormal</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Thyroid function test abnormal</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Positive with E.coli</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Escherichia coli test positive</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Escherichia test positive</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121123</reactionstartdate>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121203</testdate>
				<testname>Anti-thyroid antibody</testname>
				<testresult>64</testresult>
				<testunit>IU/ml</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121203</testdate>
				<testname>Anti-thyroid antibody</testname>
				<testresult>64</testresult>
				<testunit>IU/ml</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Biopsy skin</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121123</testdate>
				<testname>Blood creatinine</testname>
				<testresult>192</testresult>
				<testunit>umol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Blood creatinine</testname>
				<testresult>132</testresult>
				<testunit>umol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121206</testdate>
				<testname>Blood creatinine</testname>
				<testresult>106</testresult>
				<testunit>umol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121213</testdate>
				<testname>Blood creatinine</testname>
				<testresult>131</testresult>
				<testunit>umol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121123</testdate>
				<testname>Blood urea</testname>
				<testresult>23.8</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121123</testdate>
				<testname>Blood urea</testname>
				<testresult>23.8</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Blood urea</testname>
				<testresult>14.3</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Blood urea</testname>
				<testresult>14.3</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121206</testdate>
				<testname>Blood urea</testname>
				<testresult>12.4</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121206</testdate>
				<testname>Blood urea</testname>
				<testresult>12.4</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121123</testdate>
				<testname>Eosinophil count</testname>
				<testresult>3.56</testresult>
				<testunit>g/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121123</testdate>
				<testname>Eosinophil count</testname>
				<testresult>3.56</testresult>
				<testunit>g/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Immunology test</testname>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>NISISCO</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationnumb>20-818</drugauthorizationnumb>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit code="032"/>
				<drugdosagetext>1 DF, daily (160 mg vals and 12.5 mg hctz)</drugdosagetext>
				<drugdosageform normalized="film-coated tablet">Film-Coated Tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hypertension</drugindication>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-11-23</drugenddate>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>HYDROCHLOROTHIAZIDE</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>VALSARTAN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blister</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blister</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dermatitis bullous</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dermatitis bullous</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eosinophilia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eosinophilia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Erythema</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Erythema</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Escherichia test positive</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Escherichia test positive</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypotension</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypotension</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Oedema peripheral</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Oedema peripheral</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pruritus</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pruritus</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal failure</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal failure</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Thyroid function test abnormal</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Thyroid function test abnormal</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Urticaria</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Urticaria</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>ATENOLOL </medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugstructuredosagenumb>100</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>100 mg, BID</drugdosagetext>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-11-23</drugenddate>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ATENOLOL</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blister</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blister</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dermatitis bullous</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dermatitis bullous</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eosinophilia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eosinophilia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Erythema</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Erythema</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Escherichia test positive</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Escherichia test positive</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypotension</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypotension</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Oedema peripheral</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Oedema peripheral</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pruritus</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pruritus</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal failure</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal failure</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Thyroid function test abnormal</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Thyroid function test abnormal</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Urticaria</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Urticaria</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>TAHOR</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugstructuredosagenumb>10</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>10 mg, one tablet daily</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Dyslipidaemia</drugindication>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-11-23</drugenddate>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ATORVASTATIN CALCIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>GLUCOPHAGE</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugstructuredosagenumb>500</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>500 mg, BID</drugdosagetext>
				<drugdosageform normalized="coated tablet">Coated tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Type 2 diabetes mellitus</drugindication>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>METFORMIN HYDROCHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>DIAMICRON</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugstructuredosagenumb>2</drugstructuredosagenumb>
				<drugstructuredosageunit code="032"/>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>2 DF, BID (40 mg)</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Type 2 diabetes mellitus</drugindication>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>GLICLAZIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>DOLIPRANE</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-11-23</drugenddate>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>PROFENID</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>2012-07-01</drugstartdate>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>KETOPROFEN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>TRAMADOL</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>2012-07-01</drugstartdate>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>TRAMADOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>KETUM</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>2012-07-01</drugstartdate>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>KETOPROFEN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>AERIUS</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>2012-07-01</drugstartdate>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>DESLORATADINE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>PRAVASTATIN</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>2012-07-01</drugstartdate>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PRAVASTATIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>AMOXICILLIN</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Blister</drugindication>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>2012-07-01</drugstartdate>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMOXICILLIN</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012FR122194, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report from a <Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">health care professional via <Semaphore x="1947545" class="Race" value="French" score="1.00" ID="C43854">French </Semaphore>Health </Semaphore>Authorities (AN20120985) forwarded License partner by Ipsen pharma (2012-SPON 532) received on 31 Dec 2012, with follow up report from other healthcare <Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">professional via <Semaphore x="1947545" class="Race" value="French" score="1.00" ID="C43854">French </Semaphore>health </Semaphore>authorities received on 31 Dec 2012 and on 18 Jan 2013. This report refers to a 79-year old female patient. The patient's medical history included <Semaphore x="2038093" class="Disease or Finding" value="Hypertension" score="1.00" ID="C3117">hypertension</Semaphore>, <Semaphore x="1869448" class="Disease or Finding" value="Dyslipidemia" score="1.00" ID="C80385">dyslipidemia</Semaphore>, <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">non <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985"><Semaphore x="733661" class="Medicine" value="Insulin" score="0.87" ID="275827">insulin </Semaphore>dependent diabetes mellitus </Semaphore></Semaphore>and vascular <Semaphore x="2294371" class="Disease or Finding" value="Nephropathy" score="1.00" ID="C34843">nephropathy </Semaphore>with <Semaphore x="1781618" class="Disease or Finding" value="Chronic Renal Failure" score="1.00" ID="C9438">chronic renal failure</Semaphore>. This polymedicated patient received Nisisco (<Semaphore x="1320437" class="Medicine" value="valsartan" score="0.49" ID="280295">valsartan</Semaphore>, <Semaphore x="675434" class="Medicine" value="Hydrochlorothiazide" score="0.49" ID="270905">hydrochlorothiazide</Semaphore>) tablet for <Semaphore x="2038093" class="Disease or Finding" value="Hypertension" score="1.00" ID="C3117">hypertension </Semaphore><Semaphore x="1545159" class="AnatomicStructure" value="Artery" score="1.00" ID="C12372">arterial </Semaphore>from an unknown date at a dose of 160/12.5 mg daily <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally</Semaphore>, <Semaphore x="168570" class="Medicine" value="Atenolol" score="0.49" ID="213117">atenolol </Semaphore>(unknown <Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">manufacturer</Semaphore>) for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of an unknown indication from an unknown start date at a dose of 100 mg BID, Tahor (<Semaphore x="170028" class="Medicine" value="atorvastatin" score="0.49" ID="286843">atorvastatin</Semaphore>) for <Semaphore x="1869448" class="Disease or Finding" value="Dyslipidemia" score="1.00" ID="C80385">dyslipidemia </Semaphore>at a dose of 10 mg one tablet daily <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally</Semaphore>, <Semaphore x="625332" class="Medicine" value="Glucophage" score="0.49" ID="239547">Glucophage </Semaphore>(<Semaphore x="857793" class="Medicine" value="metFORMIN hydrochloride" score="0.49" ID="249555">metformin hydrochloride</Semaphore>) <Semaphore x="1789915" class="AnatomicStructure" value="Coat" score="1.00" ID="C25450">coated </Semaphore>tablet for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of type 2 non <Semaphore x="733661" class="Medicine" value="Insulin" score="0.87" ID="275827">insulin </Semaphore>dependant <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">diabetes </Semaphore>from an unknown date at a dose of 500 mg BID <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally</Semaphore>, Diamicron (<Semaphore x="622815" class="Medicine - Gliclazide - Dose" value="80 mg" score="0.49" ID=""><Semaphore x="622844" class="Medicine" value="Gliclazide" score="0.49" ID="269401">gliclazide</Semaphore>) tablet <Semaphore x="2674970056458241" class="Medicine - Gliclazide - Dose" value="80 mg" score="0.49" ID="">80 mg </Semaphore></Semaphore><Semaphore x="2675030186000385" class="Medicine - Gliclazide - Frequency" value="for" score="0.49" ID="">for </Semaphore>the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of type 2 non <Semaphore x="733661" class="Medicine" value="Insulin" score="0.87" ID="275827">insulin </Semaphore>dependant <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">diabetes </Semaphore>from an unknown date at a dose of 0.5 tablet mg BID that to say 40 mg BID, <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>and Doliprane (<Semaphore x="2737985" class="MedDRA LLT" value="Analgesic drug level" score="1.00" ID="10060090">paracetamol</Semaphore>) for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of an unknown indication from an unknown start date at an unknown dose. In Aug 2012, after starting the suspect <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug </Semaphore>the patient experienced <Semaphore x="2901045" class="MedDRA LLT" value="Dermatitis bullous" score="1.00" ID="10012441">bullous eruption </Semaphore>and <Semaphore x="2934121" class="MedDRA LLT" value="Eosinophilia" score="1.00" ID="10014950">hypereosinophilia</Semaphore>. Since Aug 2012<Semaphore x="2667914" class="AnatomicStructure" value="Upper Extremity" score="1.00" ID="C12671">, occurrence of <Semaphore x="2667914" class="AnatomicStructure" value="Upper Extremity" score="1.00" ID="C12671">upper limbs </Semaphore></Semaphore><Semaphore x="1896059" class="Disease or Finding" value="Erythema" score="1.00" ID="C26901">erythema </Semaphore>with progressive <Semaphore x="2535526" class="AnatomicStructure" value="Smegma" score="1.00" ID="C33574">spread </Semaphore>to the whole <Semaphore x="1610517" class="AnatomicStructure" value="Body" score="1.00" ID="C13041">body</Semaphore>. The patient was hospitalized on 21 Nov 2012 for <Semaphore x="2901045" class="MedDRA LLT" value="Dermatitis bullous" score="1.00" ID="10012441">bullous <Semaphore x="1843713" class="Disease or Finding" value="Dermatosis" score="1.00" ID="C27554">dermatosis </Semaphore></Semaphore>and oligoanuric <Semaphore x="2459546" class="Disease or Finding" value="Renal Failure" score="1.00" ID="C4376">renal failure</Semaphore>. On 13 Nov 2012, her general <Semaphore x="2209876" class="Occupation" value="Medical Occupation" score="0.58" ID="C19254">physician </Semaphore>(GP) prescribed <Semaphore x="752187" class="Medicine" value="Ivermectin" score="0.49" ID="276637">ivermectin </Semaphore>and <Semaphore x="108837" class="Medicine" value="Amoxicillin" score="0.49" ID="281312">Amoxicillin </Semaphore>for 7 days for <Semaphore x="1606488" class="Disease or Finding" value="Blister" score="1.00" ID="C75564">blisters</Semaphore>. Then <Semaphore x="1896059" class="Disease or Finding" value="Erythema" score="1.00" ID="C26901">erythema </Semaphore><Semaphore x="2535526" class="AnatomicStructure" value="Smegma" score="1.00" ID="C33574">spread </Semaphore>and <Semaphore x="2901045" class="MedDRA LLT" value="Dermatitis bullous" score="1.00" ID="10012441">bullous <Semaphore x="2107425" class="Disease or Finding" value="Lesion" score="1.00" ID="C3824">lesions </Semaphore></Semaphore>appeared <Semaphore x="2032500" class="Disease or Finding" value="Hospitalization Required" score="1.00" ID="C50414">requiring <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalisation</Semaphore></Semaphore>. <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">Treatment </Semaphore>was not recently modified. The patient had a dog and a budgerigar at home. On admission, <Semaphore x="1889985" class="Disease or Finding" value="Eosinophilia" score="1.00" ID="C3015">eosinophilia </Semaphore>and <Semaphore x="1426763" class="Disease or Finding" value="Acute Renal Failure" score="1.00" ID="C26808">acute oligoanuric renal failure </Semaphore>was <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosed</Semaphore>. On 23 Nov 2012, due to persistent <Semaphore x="1545159" class="AnatomicStructure" value="Artery" score="1.00" ID="C12372">arterial </Semaphore><Semaphore x="2041846" class="Disease or Finding" value="Hypotension" score="1.00" ID="C3128">hypotension </Semaphore>despite adequate fluid <Semaphore x="2464778" class="Procedure" value="Resuscitation" score="1.00" ID="C50822">resuscitation </Semaphore>she was transferred in an <Semaphore x="3043968" class="MedDRA LLT" value="Intensive care" score="1.00" ID="10022519">intensive care </Semaphore>unit. The patient's clinical examination showed <Semaphore x="2937580" class="MedDRA LLT" value="Erythema" score="1.00" ID="10015150">diffuse papullar <Semaphore x="1896059" class="Disease or Finding" value="Erythema" score="1.00" ID="C26901">erythema </Semaphore></Semaphore>on <Semaphore x="2612811" class="AnatomicStructure" value="Thigh" score="1.00" ID="C33763">thigh</Semaphore>, <Semaphore x="1405315" class="AnatomicStructure" value="Abdominal Cavity" score="1.00" ID="C12664">abdomen</Semaphore>, <Semaphore x="1762050" class="AnatomicStructure" value="Chest" score="1.00" ID="C25389">chest</Semaphore>, <Semaphore x="2520062" class="AnatomicStructure" value="Shoulder" score="1.00" ID="C25203">shoulders </Semaphore>and <Semaphore x="1563494" class="AnatomicStructure" value="Back" score="1.00" ID="C13062">back</Semaphore>, and <Semaphore x="2107425" class="Disease or Finding" value="Lesion" score="1.00" ID="C3824"><Semaphore x="1851129" class="Disease or Finding" value="Diffuse Lesion" score="1.00" ID="C47826">diffuse <Semaphore x="2901045" class="MedDRA LLT" value="Dermatitis bullous" score="1.00" ID="10012441">bullous <Semaphore x="2506214" class="Disease or Finding" value="Serous Lesion" score="1.00" ID="C36120">lesions </Semaphore></Semaphore>
      </Semaphore>
     </Semaphore>
    <Semaphore x="2506214" class="Disease or Finding" value="Serous Lesion" score="1.00" ID="C36120">with serous </Semaphore>liquid inside, no Nikolski’s <Semaphore x="2521321" class="Disease or Finding" value="Sign" score="1.00" ID="C53458">sign</Semaphore>, no lesion on <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">oral </Semaphore><Semaphore x="2243600" class="AnatomicStructure" value="Mucosa" score="1.00" ID="C13166">mucous membrane</Semaphore><Semaphore x="2125426" class="AnatomicStructure" value="Lower Extremity" score="1.00" ID="C12742">, <Semaphore x="3149857" class="MedDRA LLT" value="Oedema peripheral" score="1.00" ID="10030124"><Semaphore x="2125426" class="AnatomicStructure" value="Lower Extremity" score="1.00" ID="C12742">lower <Semaphore x="3149857" class="MedDRA LLT" value="Oedema peripheral" score="1.00" ID="10030124">limbs </Semaphore></Semaphore>
      </Semaphore></Semaphore>
    <Semaphore x="3149857" class="MedDRA LLT" value="Oedema peripheral" score="1.00" ID="10030124">
     <Semaphore x="3149857" class="MedDRA LLT" value="Oedema peripheral" score="1.00" ID="10030124">oedema </Semaphore>up to <Semaphore x="2089953" class="AnatomicStructure" value="Knee Joint" score="1.00" ID="C32898">knees</Semaphore></Semaphore>, multiple <Semaphore x="3210212" class="MedDRA LLT" value="Pruritus" score="1.00" ID="10037087">itching </Semaphore><Semaphore x="2107425" class="Disease or Finding" value="Lesion" score="1.00" ID="C3824">lesions</Semaphore>. The <Semaphore x="1843527" class="Occupation" value="Dermatologist" score="1.00" ID="C17816">dermatologist </Semaphore>advised on 26 Nov 2012 as probable <Semaphore x="1652068" class="Disease or Finding" value="Bullous Pemphigoid" score="1.00" ID="C84389">bullous pemphigoid</Semaphore>. On admission in a dermatologic unit on 27 Nov 2012, examination showed multiple <Semaphore x="2605424" class="AnatomicStructure" value="Tensor Fasciae Lata" score="1.00" ID="C53072">tense </Semaphore><Semaphore x="2901045" class="MedDRA LLT" value="Dermatitis bullous" score="1.00" ID="10012441">bullous <Semaphore x="1851129" class="Disease or Finding" value="Diffuse Lesion" score="1.00" ID="C47826">lesions </Semaphore></Semaphore>
    <Semaphore x="2107425" class="Disease or Finding" value="Lesion" score="1.00" ID="C3824">
     <Semaphore x="1851129" class="Disease or Finding" value="Diffuse Lesion" score="1.00" ID="C47826">on <Semaphore x="2937580" class="MedDRA LLT" value="Erythema" score="1.00" ID="10015150">diffuse </Semaphore></Semaphore>
     </Semaphore>
    <Semaphore x="1896059" class="Disease or Finding" value="Erythema" score="1.00" ID="C26901">erythema </Semaphore>on extension side of <Semaphore x="2667914" class="AnatomicStructure" value="Upper Extremity" score="1.00" ID="C12671"><Semaphore x="2667914" class="AnatomicStructure" value="Upper Extremity" score="1.00" ID="C12671">upper and <Semaphore x="2125426" class="AnatomicStructure" value="Lower Extremity" score="1.00" ID="C12742">lower limbs</Semaphore></Semaphore>
     <Semaphore x="2125426" class="AnatomicStructure" value="Lower Extremity" score="1.00" ID="C12742">, </Semaphore></Semaphore><Semaphore x="1563494" class="AnatomicStructure" value="Back" score="1.00" ID="C13062">back </Semaphore>and <Semaphore x="1918283" class="AnatomicStructure" value="Face" score="1.00" ID="C13071">face</Semaphore>, <Semaphore x="2673761" class="Disease or Finding" value="Urticaria" score="1.00" ID="C3432">urticaria </Semaphore>on <Semaphore x="2614087" class="AnatomicStructure" value="Thorax" score="1.00" ID="C12799">thorax </Semaphore>and <Semaphore x="1405315" class="AnatomicStructure" value="Abdominal Cavity" score="1.00" ID="C12664">abdomen</Semaphore>. The patient's complementary examinations include <Semaphore x="2525335" class="Procedure" value="Skin Biopsy" score="1.00" ID="C51692">skin biopsy </Semaphore>that showed auto immune <Semaphore x="2901045" class="MedDRA LLT" value="Dermatitis bullous" score="1.00" ID="10012441">bullous <Semaphore x="1843713" class="Disease or Finding" value="Dermatosis" score="1.00" ID="C27554">dermatosis </Semaphore></Semaphore>of <Semaphore x="1829687" class="Disease or Finding" value="Cutaneous Sarcoidosis" score="1.00" ID="C34996">dermal </Semaphore><Semaphore x="1891276" class="AnatomicStructure" value="Epidermis" score="1.00" ID="C12708">epidermal </Semaphore>junction <Semaphore x="2592399" class="Race" value="Sugpiaq" score="1.00" ID="C44488">suggesting </Semaphore><Semaphore x="1652068" class="Disease or Finding" value="Bullous Pemphigoid" score="1.00" ID="C84389">bullous pemphigoid</Semaphore>. <Semaphore x="2046472" class="Procedure" value="Immunoblot Analysis" score="1.00" ID="C17638">Immunoblot assay </Semaphore><Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">results </Semaphore>were expected. <Semaphore x="2748952" class="MedDRA LLT" value="Anti-thyroid antibody" score="1.00" ID="10060325">Anti <Semaphore x="2047985" class="Procedure" value="Immunology Test" score="0.58" ID="C16723"><Semaphore x="2625132" class="Procedure" value="Thyroperoxidase Measurement" score="1.00" ID="C96639">thyroid peroxidase </Semaphore>antibodies </Semaphore></Semaphore>were at 64UI/ml on 03 Dec 2012 (performed because altered <Semaphore x="2618121" class="Disease or Finding" value="Thyroid Gland Abscess" score="1.00" ID="C27115">thyroid </Semaphore>function). CBEU (unspecified) positive with E.coli on 23 Nov 2012. Creatininaemia at 192 습mol/L on 23 Nov 2012, at 132 습mol/L on 30 Nov 2012, 106 습mol/L on 06 Dec 2012, 131 습mol/L on 13 Dec 2012. The patient's <Semaphore x="2819249" class="MedDRA LLT" value="Blood urea" score="1.00" ID="10005845"><Semaphore x="2406017" class="AnatomicStructure" value="Plasma" score="1.00" ID="C13356">plasma </Semaphore><Semaphore x="1607623" class="Procedure" value="Blood Urea Nitrogen Measurement" score="1.00" ID="C61019">blood <Semaphore x="1316129" class="Medicine" value="Urea" score="0.49" ID="194669">urea </Semaphore></Semaphore>
     <Semaphore x="1607623" class="Procedure" value="Blood Urea Nitrogen Measurement" score="1.00" ID="C61019">nitrogen </Semaphore></Semaphore>(<Semaphore x="1607623" class="Procedure" value="Blood Urea Nitrogen Measurement" score="1.00" ID="C61019">BUN</Semaphore>) was at 23.8 mmol/L on 23 Nov 2012, at 14.3 mmol/L on 30 Nov 2012, 12.7 mmol/L on 30 Nov 2012 and 12.4 mmol/L on 06 Dec 2012. The patient's <Semaphore x="1889898" class="Procedure" value="Eosinophil Count" score="1.00" ID="C64550">eosinophils </Semaphore>count was at 3.56 g/l on 23 Nov 2012. <Semaphore x="2053299" class="Disease or Finding" value="Infectious Disorder" score="1.00" ID="C26726">Infectious </Semaphore>bovine <Semaphore x="3234804" class="MedDRA LLT" value="Rhinotracheitis" score="1.00" ID="10051497">rhinotracheitis </Semaphore>(BHV), AHV, CHV <Semaphore x="3245717" class="MedDRA LLT" value="Serology negative" score="1.00" ID="10050410">serologies were <Semaphore x="2265745" class="Disease or Finding" value="Negative Patch Test" score="1.00" ID="C35633">negative</Semaphore></Semaphore>. Local <Semaphore x="2317659" class="Disease or Finding" value="Non-Neoplastic Skin Disorder" score="0.78" ID="C27555">skin </Semaphore>care was given as <Semaphore x="1606488" class="Disease or Finding" value="Blister" score="1.00" ID="C75564">bullae </Semaphore>boring and <Semaphore x="1183505" class="Medicine" value="Silver Nitrate" score="0.49" ID="299191"><Semaphore x="2521479" class="Procedure" value="Silver Staining Method" score="1.00" ID="C23018">silver </Semaphore>nitrate </Semaphore>application. Topical corticoids on the whole <Semaphore x="1610517" class="AnatomicStructure" value="Body" score="1.00" ID="C13041">body</Semaphore>. After transfer in dermatologic unit, appearance of <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">oral </Semaphore><Semaphore x="1606488" class="Disease or Finding" value="Blister" score="1.00" ID="C75564">bullae </Semaphore>recovering with local and systemic corticoids. <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">Diagnosis </Semaphore>hypothesis was given as <Semaphore x="1554896" class="Disease or Finding" value="Atypia Confined to the Basal and Parabasal Epithelial Layers" score="1.00" ID="C61602">atypical </Semaphore><Semaphore x="3176661" class="MedDRA LLT" value="Pemphigoid" score="1.00" ID="10034277"><Semaphore x="2384353" class="Disease or Finding" value="Pemphigoid" score="1.00" ID="C34908"><Semaphore x="1652068" class="Disease or Finding" value="Bullous Pemphigoid" score="1.00" ID="C84389">bullous <Semaphore x="3176661" class="MedDRA LLT" value="Pemphigoid" score="1.00" ID="10034277">pemphigoid</Semaphore></Semaphore>
      </Semaphore>
     , <Semaphore x="3176661" class="MedDRA LLT" value="Pemphigoid" score="1.00" ID="10034277">cicatricial </Semaphore><Semaphore x="2317659" class="Disease or Finding" value="Non-Neoplastic Skin Disorder" score="0.78" ID="C27555">pemphigoid </Semaphore></Semaphore>or <Semaphore x="2712652" class="MedDRA LLT" value="Acquired epidermolysis bullosa" score="1.00" ID="10056508">acquired <Semaphore x="1891458" class="Disease or Finding" value="Epidermolysis Bullosa" score="1.00" ID="C67383">epidermolysis bullosa</Semaphore></Semaphore>. <Semaphore x="2334476" class="Disease or Finding" value="Ophthalmoplegia" score="1.00" ID="C79697">Ophthalmologic </Semaphore>examination did not show <Semaphore x="1917161" class="AnatomicStructure" value="Eye" score="1.00" ID="C12401">eye </Semaphore><Semaphore x="2901045" class="MedDRA LLT" value="Dermatitis bullous" score="1.00" ID="10012441"><Semaphore x="2107425" class="Disease or Finding" value="Lesion" score="1.00" ID="C3824">lesions </Semaphore>of <Semaphore x="1652068" class="Disease or Finding" value="Bullous Pemphigoid" score="1.00" ID="C84389">bullous </Semaphore></Semaphore>
    <Semaphore x="3176661" class="MedDRA LLT" value="Pemphigoid" score="1.00" ID="10034277">
     <Semaphore x="2384353" class="Disease or Finding" value="Pemphigoid" score="1.00" ID="C34908">
      <Semaphore x="1652068" class="Disease or Finding" value="Bullous Pemphigoid" score="1.00" ID="C84389">pemphigoid</Semaphore></Semaphore></Semaphore>. <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">Oral </Semaphore>examination showed post bullous <Semaphore x="1895830" class="Disease or Finding" value="Erosion" score="1.00" ID="C50443">erosions </Semaphore>of <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">oral </Semaphore><Semaphore x="2243600" class="AnatomicStructure" value="Mucosa" score="1.00" ID="C13166">mucous membrane</Semaphore>. One <Semaphore x="1606488" class="Disease or Finding" value="Blister" score="1.00" ID="C75564">bulla </Semaphore>on posterior and lateral pharyngeal wall at the <Semaphore x="2350152" class="AnatomicStructure" value="Oropharynx" score="1.00" ID="C12762">oropharynx </Semaphore><Semaphore x="779631" class="Medicine" value="Level" score="0.49" ID="187620">level</Semaphore>. No cavum <Semaphore x="1409018" class="Disease or Finding" value="Abnormality" score="1.00" ID="C9440">abnormality</Semaphore>. Favorable cutaneous <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>with local and systemic corticoids. It was concluded that probable <Semaphore x="1652068" class="Disease or Finding" value="Bullous Pemphigoid" score="1.00" ID="C84389">bullous pemphigoid </Semaphore>and <Semaphore x="1426763" class="Disease or Finding" value="Acute Renal Failure" score="1.00" ID="C26808">acute functional renal failure</Semaphore>. <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">Drug </Semaphore>induced reaction non excluded. On an unspecified date, <Semaphore x="2046472" class="Procedure" value="Immunoblot Analysis" score="1.00" ID="C17638">immunoblot assay </Semaphore><Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">results </Semaphore>confirmed <Semaphore x="2749660" class="MedDRA LLT" value="Antibody test positive" score="1.00" ID="10061427">positive <Semaphore x="2047985" class="Procedure" value="Immunology Test" score="0.58" ID="C16723">antibodies </Semaphore></Semaphore>
    <Semaphore x="2384314" class="Procedure" value="Pemphigoid Antibody Measurement" score="1.00" ID="C81988">
     <Semaphore x="2047985" class="Procedure" value="Immunology Test" score="0.58" ID="C16723">against bullus <Semaphore x="3176661" class="MedDRA LLT" value="Pemphigoid" score="1.00" ID="10034277">pemphigoid </Semaphore></Semaphore></Semaphore>antigens BPAG2. No argument acquired bullous <Semaphore x="2934862" class="MedDRA LLT" value="Epidermolysis" score="1.00" ID="10053177">epidermolysis </Semaphore>nor for <Semaphore x="3172688" class="MedDRA LLT" value="Paraneoplastic pemphigus" score="1.00" ID="10057056">paraneoplastic <Semaphore x="2317659" class="Disease or Finding" value="Non-Neoplastic Skin Disorder" score="0.78" ID="C27555">pemphigus</Semaphore></Semaphore>. <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">Outcome </Semaphore>of the event <Semaphore x="2901045" class="MedDRA LLT" value="Dermatitis bullous" score="1.00" ID="10012441">bullous eruption </Semaphore>was reported as condition improving, for <Semaphore x="2934121" class="MedDRA LLT" value="Eosinophilia" score="1.00" ID="10014950">hypereosinophilia </Semaphore>was recovered and for <Semaphore x="1606488" class="Disease or Finding" value="Blister" score="1.00" ID="C75564">blisters </Semaphore>reported as condition <Semaphore x="1409602" class="Procedure" value="About What Time is it" score="1.00" ID="C110931">unchanged </Semaphore>while <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>for other events was not reported. The events <Semaphore x="2901045" class="MedDRA LLT" value="Dermatitis bullous" score="1.00" ID="10012441">bullous eruption</Semaphore>, <Semaphore x="2934121" class="MedDRA LLT" value="Eosinophilia" score="1.00" ID="10014950">hypereosinophilia </Semaphore>were considered as serious (<Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization</Semaphore>). Causality for the events <Semaphore x="2901045" class="MedDRA LLT" value="Dermatitis bullous" score="1.00" ID="10012441">bullous eruption</Semaphore>, <Semaphore x="2934121" class="MedDRA LLT" value="Eosinophilia" score="1.00" ID="10014950">hypereosinophilia </Semaphore>was reported as suspected. Seriousness and causality for other events were not reported.Follow up report from other healthcare <Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">professional via <Semaphore x="1947545" class="Race" value="French" score="1.00" ID="C43854">French </Semaphore>health </Semaphore>authorities received on 31 Dec 2012: Updated concentration and dosage <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">regimen </Semaphore>of Diamicron.Follow up report received from <Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">other health care professional </Semaphore><Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">via <Semaphore x="1947545" class="Race" value="French" score="1.00" ID="C43854">French </Semaphore>health </Semaphore>authorities received on 18 Jan 2013: Suspect <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug </Semaphore>atorvastatine was updated to Tahor. Immunoblot test added and <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of <Semaphore x="2934121" class="MedDRA LLT" value="Eosinophilia" score="1.00" ID="10014950">hypereosinophilia </Semaphore>was changed to recovered. Narrative updated.</narrativeincludeclinical>
				<sendercomment>MAC Nisisco: Without information on the start date of suspect drug, a proper causality assessment cannot be performed. Case will be reassessed on receipt of follow-up information.

Based on Review of available reported data does not allow for a proper causality assessment. Reported events are not assessable

MAC for atenolol: Based on review of available reported data, the causal role of atenolol cannot be ruled out for bullous dermatitis. The causal role of atenolol for acute renal failure cannot be assessed. Underlying chronic renal failure, concomitant valsartan and atorvastatin can be possible alterantive explanation for acute renal failure.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>